GRCE Stock Summary and Trading Ideas (Grace Therapeutics | NASDAQ:GRCE)

Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.

What symbol and exchange does Grace Therapeutics shares trade?

Grace Therapeutics trades on the NASDAQ stock market under the symbol GRCE.

What is Grace Therapeutics stock price doing today?

As of August 14, 2026, GRCE stock price climbed to $2.16 with 397,385 million shares trading.

What is Grace Therapeutics's Beta?

GRCE has a beta of 0.52, meaning it tends to be less sensitive to market movements. GRCE has a correlation of 0.00 to the broad based SPY ETF.

How much is Grace Therapeutics worth?

GRCE has a market cap of $45.44 million. This is considered a Sub-Micro Cap stock.

How much money does Grace Therapeutics make?

Last quarter Grace Therapeutics reported $0 in Revenue and -$.91 earnings per share. This fell short of revenue expectation by $-545,000 and missed earnings estimates by -$.73.

What are the top ETFs holding Grace Therapeutics?

The top ETF exchange traded funds that GRCE belongs to (by Net Assets): VTI, IWC.

Is Grace Therapeutics (GRCE) a good investment?

GRCE has underperformed the market in the last year with a price return of -29.9% while the SPY ETF gained +21.5%. GRCE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -1.4% and +3.8%, respectively, while the SPY returned +4.0% and +3.9%, respectively.

What are the support and resistance levels for Grace Therapeutics (GRCE)?

GRCE support price is $1.99 and resistance is $2.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRCE shares will trade within this expected range on the day.